Literature DB >> 29029067

Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae.

Fiona Fransen1,2, Kelly Hermans1, Maria J B Melchers1,2, Claudia C M Lagarde1,2, Joseph Meletiadis2,3, Johan W Mouton1,2.   

Abstract

BACKGROUND: The increase in antibiotic resistance in Gram-negative bacteria and the limited therapeutic options due to the shortage of new antibiotics have increased the interest of the 'old' antibiotic fosfomycin in the treatment of infections. However, there are contradictory reports on the pharmacodynamics of and emergence of resistance to fosfomycin.
METHODS: Time-kill assays were performed with 11 ESBL-positive and 3 ESBL-negative strains, exposing the bacteria to 2-fold static concentrations from 0.125× to 32× MIC. The sigmoid maximum effect (Emax) model was fitted to the time-kill curve data. Amplification of resistance over time was evaluated under various conditions of selective pressure by plating on 16× MIC plates.
RESULTS: Fosfomycin was bactericidal for all strains within 8 h. Using the Emax model, no significant differences between strains were observed for the pharmacodynamic parameters. However, the large variation in Hill slope factors for Escherichia coli of 0.87 up to 4.02 indicates that the killing behaviour appears to be more time dependent for some strains but concentration dependent for others. In the fosfomycin-exposed cultures under low and high selective pressure (≥2× MIC) the median resistance proportions between the resistant and total population increased from ≤2 × 10-6 (T = 0 h) to 0.652-0.899 (T = 24 h). Resistance appeared stable after repeated subculturing.
CONCLUSIONS: Killing behaviour of fosfomycin does not only differ between species but also within species and may have an impact on the design of optimal dosing regimens. Although fosfomycin was bactericidal against all strains (re)growth of resistant subpopulations occurred relatively fast. This may limit the use of fosfomycin as a single drug therapy.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29029067     DOI: 10.1093/jac/dkx328

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  In Vitro Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes.

Authors:  Tze-Peng Lim; Jocelyn Qi-Min Teo; Audrey Wei-Ling Goh; Si-Xuan Tan; Tse-Hsien Koh; Winnie Hui-Ling Lee; Yiying Cai; Thuan-Tong Tan; Andrea Lay-Hoon Kwa
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

2.  Mismatch-CRISPRi Reveals the Co-varying Expression-Fitness Relationships of Essential Genes in Escherichia coli and Bacillus subtilis.

Authors:  John S Hawkins; Melanie R Silvis; Byoung-Mo Koo; Jason M Peters; Hendrik Osadnik; Marco Jost; Cameron C Hearne; Jonathan S Weissman; Horia Todor; Carol A Gross
Journal:  Cell Syst       Date:  2020-10-19       Impact factor: 10.304

3.  Leveraging Antimicrobial Stewardship in the Emergency Department to Improve the Quality of Urinary Tract Infection Management and Outcomes.

Authors:  Sarah C J Jorgensen; Samantha L Yeung; Mira Zurayk; Jill Terry; Maureen Dunn; Paul Nieberg; Jean Pallares; Annie Wong-Beringer
Journal:  Open Forum Infect Dis       Date:  2018-05-02       Impact factor: 3.835

4.  Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing Escherichia coli with Canine Ex Vivo Modeling: A Pilot Study.

Authors:  Kazuki Harada; Takae Shimizu; Koji Kawaguchi; Takeshi Furuhashi; Genki Ishihara
Journal:  Antibiotics (Basel)       Date:  2020-05-05

5.  Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Authors:  Luka Bielen; Robert Likic
Journal:  Ther Adv Infect Dis       Date:  2019-06-24

Review 6.  Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.

Authors:  Roberta Maria Antonello; Stefano Di Bella; Alberto Enrico Maraolo; Roberto Luzzati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-02-18       Impact factor: 3.267

7.  Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.

Authors:  Iain J Abbott; Elke van Gorp; Kelly L Wyres; Steven C Wallis; Jason A Roberts; Joseph Meletiadis; Anton Y Peleg
Journal:  J Antimicrob Chemother       Date:  2022-04-27       Impact factor: 5.758

8.  Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).

Authors:  Kathryn M Thomson; Calie Dyer; Feiyan Liu; Kirsty Sands; Edward Portal; Maria J Carvalho; Matthew Barrell; Ian Boostrom; Susanna Dunachie; Refath Farzana; Ana Ferreira; Francis Frayne; Brekhna Hassan; Ellis Jones; Lim Jones; Jordan Mathias; Rebecca Milton; Jessica Rees; Grace J Chan; Delayehu Bekele; Abayneh Mahlet; Sulagna Basu; Ranjan K Nandy; Bijan Saha; Kenneth Iregbu; Fatima Modibbo; Stella Uwaezuoke; Rabaab Zahra; Haider Shirazi; Najeeb U Syed; Jean-Baptiste Mazarati; Aniceth Rucogoza; Lucie Gaju; Shaheen Mehtar; Andre N H Bulabula; Andrew Whitelaw; Johan G C van Hasselt; Timothy R Walsh
Journal:  Lancet Infect Dis       Date:  2021-08-09       Impact factor: 25.071

9.  Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species.

Authors:  Lin Liu; Tong Jiang; Jia Zhou; Yikun Mei; Jinyang Li; Jingcong Tan; Luqi Wei; Jingquan Li; Yibing Peng; Changbin Chen; Ning-Ning Liu; Hui Wang
Journal:  Microb Biotechnol       Date:  2021-05-06       Impact factor: 5.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.